The genomics team at TTCRC is integrated with the other research subgroups and provides support and solutions to other investigators working in different areas for e.g. the MRD team, the gall bladder cancer research program and other solid tumour research programs. One of the principal aims of the team in last couple of years is to refine the genetic risk stratification and genomic characterisation of the precursor B-Cell Acute Lymphoblastic Leukaemia (BCP-ALL) through multimodal genomic profiling.
Research
TTCRC Core Genomic Facility
The genomics team at TTCRC is integrated with the other research subgroups and provides support and solutions to other investigators working in different areas for e.g. the MRD team, the gall bladder cancer research program and other solid tumour research programs. One of the principal aims of the team in last couple of years is to refine the genetic risk stratification and genomic characterisation of the precursor B-Cell Acute Lymphoblastic Leukaemia (BCP-ALL) through multimodal genomic profiling.
Minimal residual disease (MRD) monitoring is an important predictor of outcome in childhood acute lymphoblastic leukemia (ALL). On achieving accreditation by the EuroMRD, we have now successfully established the assay based on a quantitative PCR approach. Compared to the classic flow based monitoring, qPCR MRD is more sensitive and hence reliably quantifies the residual disease in a group of uniformly treated patients, assessed in both frontline and relapsed protocols.
Minimal Residual Disease Monitoring
Team
Debdutta Ganguli
Administrative Lead
Mayur Parihar
Clinical Scientist Cytogenetics and Genomics
Binuja Varma
TCS Life Science Sr. Scientist
Rubina Islam
Senior Research Assistant
Sayantani Mitra
Research Assistant.
Uzma Zaheer
Research Assistant
Pritha Dasgupta
Anushka Ojha
Sreyasree Dhar
Research Assistant.
Debparna Saha
Research Assistant.
Lab
Previous
Next